Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X about a recent paper by Masatoshi Kudo, Professor and Chairman at the Department of Gastroenterology and Hepatology of Kindai University Faculty of Medicine, published in The Lancet:
“LEAP-012: TACE with/without lenvatinib plus pembrolizumab for intermediate risk HCC.
- No difference in OS
- Grade 3+ AE 71% in combo arm, and 32% with TACE alone
In my opinion this is not an effective, cost-effective, or ‘well-tolerated’ regimen.”
Authors: Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Richard Finn, Josep Llovet et al.
Nina Niu Sanford is an Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital. She specializes in treating gastrointestinal cancers and actively participates in clinical trials combining high-dose radiation therapy with immunotherapy.
Additionally, she researches healthcare access disparities and conducts pan-cancer outcomes research using large databases.
More posts featuring Nina Niu Sanford.
